原发性纵隔大B细胞淋巴瘤中期FDG-PET/CT阳性的预测价值较差
该回顾性研究纳入2006至2014年间在本机构连续治疗的36例原发性纵隔大B细胞淋巴瘤患者,所有中期FDG-PET/CT阳性者均接受了组织学再分期。结果显示,17/36例中期FDG-PET/CT视觉评估为阳性,其中14例Deauville评分为4分;组织学再分期除1例外均为阴性,仅见炎症和/或纤维化。中位随访48.5个月后共5例复发,阳性组2例、阴性组3例。作者认为中期FDG-PET/CT阳性在绝大多数病例中并不反映活动性疾病持续存在,其阳性预测价值较差,应谨慎使用。
要点
- 36例原发性纵隔大B细胞淋巴瘤患者中,17例中期FDG-PET/CT视觉评估为阳性。
- 17例阳性患者中14例Deauville评分为4分,组织学再分期除1例外均为阴性。
- 中位随访48.5个月,阳性组复发2例、阴性组复发3例,复发率似乎相似。
核心结论
- 中期FDG-PET/CT阳性在绝大多数原发性纵隔大B细胞淋巴瘤病例中不反映活动性疾病持续存在。
- 无论中期FDG-PET/CT结果和判读标准如何,复发率似乎相似。
- 中期FDG-PET/CT的阳性预测价值较差,在原发性纵隔大B细胞淋巴瘤中应谨慎使用。
研究设计与样本
- 回顾性研究,纳入2006年至2014年间在本机构连续治疗的36例原发性纵隔大B细胞淋巴瘤患者。
- 所有中期FDG-PET/CT阳性患者均接受组织学再分期:15例行残留病灶手术减瘤,2例行CT引导下空心针活检。
- 所有FDG-PET/CT均按较新的Deauville标准进行二次判读。
主要发现
- 视觉评估判定中期FDG-PET/CT阳性者为17/36例,其中14例Deauville评分为4分。
- 组织学再分期除1例外均为阴性,显示炎症和/或纤维化。
- 中位随访48.5个月,共5例复发,阳性FDG-PET/CT组2例,阴性FDG-PET/CT组3例。
关键数值与推荐
- 中期FDG-PET/CT阳性判定采用视觉评估,阳性17/36例。
- 阳性患者中14例Deauville评分为4分。
- 组织学再分期阴性者显示炎症和/或纤维化。
临床怎么用
- 原文结论指出中期FDG-PET/CT阳性预测价值较差,在原发性纵隔大B细胞淋巴瘤中应谨慎使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Though commonly used to assess response to therapy, the prognostic value of interim FDG-PET/CT in Primary Mediastinal Large B-cell Lymphoma (PMBCL) is unclear. METHODS: We conducted a retrospective study on 36 consecutive patients treated at our institution for a PMBCL between 2006 and 2014. All patients with a positive interim FDG-PET/CT had undergone histological restaging consisting either in a surgical debulking of the residual lesion (15 patients) or a CT-guided core needle biopsy (two patients). All FDG-PET/CT were secondarily reviewed according to the more recent Deauville criteria. RESULTS: Interim FDG-PET/CT was considered positive in 17/36 patients using visual evaluation. Among these patients, 14 had a Deauville score of 4. Histological restaging was negative in all but one case, showing inflammation and/or fibrosis. After a median follow-up of 48.5 months, a total of five patients have relapsed, two patients in the positive FDG-PET/CT group, and three patients in the negative FDG-PET/CT group, respectively. CONCLUSIONS: These data indicate that a positive interim FDG-PET/CT does not reflect persistence of active disease in the vast majority of PMBCL cases. The relapse rate appears similar regardless of interim FDG-PET/CT results and interpretation criteria. This suggests that interim FDG-PET/CT has a poor positive predictive value, thus kt should be used with caution in PMBCL.
引用
- Lazarovici J, Terroir M, Arfi-Rouche J, et al. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017. PMID: 28634685. doi:10.1007/s00259-017-3758-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。